Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy.

Trial Profile

Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 14 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 13 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top